ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0464

JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review
Abstract Number: 0135

Janus Kinase Inhibitors in Severe and Refractory Inflammatory Ocular Pathology. Cases Reports and Literature Review
Abstract Number: 1285

Joint Injection Workflow in Rheumatology – an Opportunity to Improve Efficiency and Physician Satisfaction
Abstract Number: 1382

Juvenile Eosinophilic Fasciitis: A Single-Center Cohort
Abstract Number: 1371

Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
Abstract Number: 0515

Juvenile Systemic Sclerosis Treatment Practices in an International Cohort and Comparison to Recent SHARE Consensus Guidelines
Abstract Number: 2153

Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis
Abstract Number: 1178

Key Features of Human Fibrosing Interstitial Lung Disease Are Captured in a Preclinical Mouse Model upon Repetitive, but Not Single Intratracheal Bleomycin Dosing
Abstract Number: 1194

Key Self-reported Determinants of COVID-19 Vaccine Acceptance Among Persons with and Without Autoimmune Disease
Abstract Number: 0617

Killer Cell Immunoglobulin Receptor and Class I HLA Genetic Variability in South-eastern Spanish Rheumatoid Arthritis Patients
Abstract Number: 0870

Knee Acoustic Emissions as a Noninvasive Biomarker of Articular Health in Juvenile Idiopathic Arthritis
Abstract Number: 1781

Knee Pain Is Highly Associated with Ankle/Foot Pain, Arch Height, and Arch Flexibility: The Johnston County Osteoarthritis Project
Abstract Number: 0990

KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with SLE: Results of a Phase Ib Multiple Ascending Dose Study
Abstract Number: 2027

Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
Abstract Number: 0090

Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].